Please use this identifier to cite or link to this item:
Title: A mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson's disease patients
Authors: Deus, Cláudia M. 
Pereira, Susana P.
Cunha-Oliveira, Teresa 
Teixeira, José
Simões, Rui F. 
Cagide, Fernando
Benfeito, Sofia
Borges, Fernanda
Raimundo, Nuno 
Oliveira, Paulo J.
Keywords: Human skin fibroblasts; Metabolism; Mitochondria; Mitochondriotropic antioxidant; Sporadic Parkinson's disease
Issue Date: 2021
Publisher: Elsevier
Project: info:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/BIA-MOL/28607/2017/PT/Redox-active phytochemicals triggering mitochondrial hormesis: developing a new generation of cosmetic active ingredients 
info:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/BTM-SAL/29297/2017/PT/Development and validation of innovative screening methods for mitochondrial health modulators 
info:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/MED-FAR/29391/2017/PT/Development of Novel Mitochondria-Targeted Antioxidants for Improving SOD1-Familial Amyotrophic Lateral Sclerosis Phenotype 
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04539/2020/PT 
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP/04539/2020/PT 
info:eu-repo/grantAgreement/FCT/POR_CENTRO/SFRH/BD/100341/2014/PT/An Innovative Epigenetic Engineering Approach to Reverse the Parkinson Disease Cell State 
info:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH/BPD/116061/2016/PT/Exercising the Future: Voluntary Exercise During Gestational Diabetes to Improve Cardiac Function and Mitochondrial Function in the Offspring 
info:eu-repo/grantAgreement/EC/H2020/857524/EU/Multidisciplinary Institute of Ageing - Portugal 
info:eu-repo/grantAgreement/EC/FP7/337327/EU/Mitochondria, Peroxisomes and Lysosomes - the "menage a trois" of cellular metabolism 
Serial title, monograph or event: Redox Biology
Volume: 45
Abstract: Parkinson's Disease (PD) is a neurodegenerative disorder affecting more than 10 million people worldwide. Currently, PD has no cure and no early diagnostics methods exist. Mitochondrial dysfunction is presented in the early stages of PD, and it is considered an important pathophysiology component. We have previously developed mitochondria-targeted hydroxycinnamic acid derivatives, presenting antioxidant and iron-chelating properties, and preventing oxidative stress in several biological models of disease. We have also demonstrated that skin fibroblasts from male sporadic PD patients (sPD) presented cellular and mitochondrial alterations, including increased oxidative stress, hyperpolarized and elongated mitochondria and decreased respiration and ATP levels. We also showed that forcing mitochondrial oxidative phosphorylation (OXPHOS) in sPD fibroblasts uncovers metabolic defects that were otherwise hidden. In this work, we tested the hypothesis that a lead mitochondria-targeted hydroxycinnamic acid derivative would revert the phenotype found in skin fibroblasts from sPD patients. Our results demonstrated that treating human skin fibroblasts from sPD patients with non-toxic concentrations of AntiOxCIN4 restored mitochondrial membrane potential and mitochondrial fission, decreased autophagic flux, and enhanced cellular responses to stress by improving the cellular redox state and decreasing reactive oxygen species (ROS) levels. Besides, fibroblasts from sPD patients treated with AntiOxCIN4 showed increased maximal respiration and metabolic activity, converting sPD fibroblasts physiologically more similar to their sex- and age-matched healthy controls. The positive compound effect was reinforced using a supervised machine learning model, confirming that AntiOxCIN4 treatment converted treated fibroblasts from sPD patients closer to the phenotype of control fibroblasts. Our data points out a possible mechanism of AntiOxCIN4 action contributing to a deeper understanding of how the use of mitochondria-targeted antioxidants based on a polyphenol scaffold can be used as potential drug candidates for delaying PD progression, validating the use of fibroblasts from sPD patients with more active OXPHOS as platforms for mitochondria-based drug development.
ISSN: 22132317
DOI: 10.1016/j.redox.2021.102037
Rights: openAccess
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
IIIUC - Artigos em Revistas Internacionais
I&D MIA PORTUGAL - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
Deus et al. - 2021 - Redox Biology(2)-annotated.pdf15.6 MBAdobe PDFView/Open
Show full item record


checked on Nov 17, 2022


checked on Nov 15, 2022

Page view(s)

checked on Feb 20, 2024


checked on Feb 20, 2024

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons